Abstract:134 Objectives: Pancreatic cancer (PaCa) is the second most frequent digestive cancer in the US. It is one of the most aggressive malignancies in the world, with a median survival time of less than 6 months and a 5-year overall survival rate of less than 6%. The poor prognosis of PaCa is largely due to its advanced stage at diagnosis, with >80% of patients presenting with locally advanced or metastatic disease, and the lack of efficient therapeutic options. The survival rate for PaCa can only be improved if early diagnosis can be achieved and a better PaCa therapeutic strategy is developed. The development of an efficient, multifunctional PaCa theranostic system is urgently needed to improve PaCa patient management. In that context, the possibility of using a radioactive theranostic pair such as 86/90Y, with identical radiolabeling chemistry, attached to a same targeted moiety is extremely attractive. Overexpression of tissue factor (TF) has been associated with increased tumor growth, tumor angiogenesis, and metastatic potential in many malignancies, including pancreatic cancer. TF is expressed on 77% of pancreatic intraepithelial neoplasms, with no expression on health adjacent ductal tissue, and on 91% of intraductal papillary mucinous neoplasms, with higher expression indicating more extensive dysplasia. We propose the use of a TF-targeted monoclonal antibody (ALT836) conjugated with the pair 86/90Y as a theranostic agent against pancreatic cancer. Methods: The anti-TF antibody, ALT836 (Altor Bioscience Corp) was conjugated with diethylenetriaminepentaacetic acid (DTPA) for radiolabeling with two yttrium isotopes: 86Y (t1/2: 14.7 h, a positron emitter) and 90Y (t1/2: 64 h, a higher energy beta-emitter). Serial PET imaging with the positron-emitter 86Y-DTPA-ALT836 was conducted to map the biodistribution and investigate the pharmacokinetics of the tracer in BXPC-3 tumor-bearing mice. For therapeutic studies, four groups were employed: 90Y-DTPA-ALT836 (120 µCi, 45 µg), 90Y-DTPA-IgG (an isotype control, 120 µCi, 45 µg), ALT836 only (45 µg), and PBS only. Tumor growth and mouse body weight were monitored for 15 days. Blood analyses were performed in all groups at 0, 7, and 15 days post-injection, and histological analysis also compared tumors and main organs pre- and post-therapy. Cerenkov luminescence imaging was also performed for the 90Y-injected mice throughout the course of the study to qualitatively map the biodistribution of 90Y-DTPA-ALT836. Results: The uptake of 86Y-DTPA-ALT836 in BXPC-3 xenograft tumors was high and increased over time (from 8.6 ± 2.4 %ID/g at 4 h p.i. to 27.3 ± 11.1 %ID/g at 48 h, n=5), with the liver showing the highest off-target accumulation at around 11.5 %ID/g at all time points. Ex vivo biodistribution studies further verified this trend, with tumor uptake of 34.8 ± 14.9 %ID/g. Cerenkov imaging demonstrated persistent uptake of 90Y-DTPA-ALT836 in the BXPC-3 tumors throughout the entire study. In therapeutic studies, 90Y-DTPA-ALT836 was found to slow tumor growth relative to the control groups and had significantly smaller (p<0.05) tumor volumes at 13 days p.i. Histological analysis of ex vivo tissues revealed significant damage to the treated tumors. Conclusions: The use of the 86/90Y theranostic pair allows PET imaging with excellent tumor-to-background contrast and treatment of TF-expressing pancreatic tumors. While promising therapeutic outcomes were achieved, the treatment with 90Y-DTPA-ALT836 requires further investigation in order to identify optimum injection and dosage regimen and to minimize off-target doses.

Pathological Expression of Tissue Factor Confers Promising Antitumor Response to A Novel Therapeutic Antibody Sc1 in Triple Negative Breast Cancer and Pancreatic Adenocarcinoma

Tissue Factor Overexpression in Triple-Negative Breast Cancer Promotes Immune Evasion by Impeding T-cell Infiltration and Effector Function.

Treating Tissue Factor-Positive Cancers with Antibody-Drug Conjugates That Do Not Affect Blood Clotting

Antitumor effect of humanized anti‑tissue factor antibody‑drug conjugate in a model of peritoneal disseminated pancreatic cancer

Antitumor effect of antitissue factor antibody-MMAE conjugate in human pancreatic tumor xenografts

Evaluation of the antitumor mechanism of antibody-drug conjugates against tissue factor in stroma-rich allograft models

Tissue factor promotes TREX1 protein stability to evade cGAS-STING innate immune response in pancreatic ductal adenocarcinoma

Characterization of a Novel Bispecific Antibody Targeting Tissue Factor-Positive Tumors with T Cell Engagement

86/90Y-Labeled Monoclonal Antibody Targeting Tissue Factor for Pancreatic Cancer Theranostics

Tumor-Specific Silencing of Tissue Factor Suppresses Metastasis and Prevents Cancer-Associated Hypercoagulability.

The Antitumor Activity Of Tcr-Mimic Antibody-Drug Conjugates (Tcrm-Adcs) Targeting The Intracellular Wilms Tumor 1 (Wt1) Oncoprotein

Anti‐tissue factor antibody conjugated with monomethyl auristatin E or deruxtecan in pancreatic cancer models

Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer

Preparation of truncated tissue factor antineuropilin-1 monoclonal antibody conjugate and identification of its selective thrombosis in tumor blood vessels.

Tissue factor: A link between metastatic colorectal cancer and thrombosis in patients in the CALGB (Alliance)/SWOG 80405 trial.

Preclinical characterization of XB002, an anti-tissue factor antibody-drug conjugate for the treatment of solid tumors

ImmunoPET of tissue factor expression in triple-negative breast cancer with a radiolabeled antibody Fab fragment

Targeting Transmembrane Tnf-Alpha Suppresses Breast Cancer Growth

Tissue factor overexpression promotes resistance to KRAS-G12C inhibition in non-small cell lung cancer

Tissue Factor As a New Target for Tumor Therapy—killing Two Birds with One Stone: a Narrative Review

Y-86/90-based Theranostics Targeting Tissue Factor in a Pancreatic Tumor Model